Clinical Characteristics and Treatment Outcomes of Patients With Advanced Germ Cell Tumor Treated at a Tertiary Cancer Center in Brazil
| Autor: | Diogo Assed Bastos, David Queiroz Borges Muniz, William C. Nahas, Allan Andresson Lima Pereira, Jamile Almeida-Silva, Carlos Dzik, Adriana de Godoy, Giuliano Guglielmetti, Gabriel Yoshiyuki Watarai, Bruno Rodriguez Pereira, Vitor Fiorin de Vasconcellos |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Oncology
Adult Male Cancer Research medicine.medical_specialty Adolescent Treatment outcome lcsh:RC254-282 Chorionic Gonadotropin Disease-Free Survival Tertiary Care Centers 03 medical and health sciences Young Adult 0302 clinical medicine Pharmacotherapy Drug Therapy Testicular Neoplasms Internal medicine medicine Original Report Humans 030212 general & internal medicine Young adult Retrospective Studies business.industry Cancer Retrospective cohort study Middle Aged Neoplasms Germ Cell and Embryonal lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Prognosis medicine.anatomical_structure Treatment Outcome 030220 oncology & carcinogenesis Multivariate Analysis Germ cell tumors alpha-Fetoproteins business Developed country Germ cell Brazil |
| Zdroj: | Journal of Global Oncology Journal of Global Oncology, Vol 5, Pp 1-8 (2019) |
| ISSN: | 2378-9506 |
| Popis: | PURPOSE Reported treatment outcomes for patients with advanced germ cell tumors (aGCT) are based mainly on series from developed nations. Data from low- and middle-income countries are underrepresented. MATERIAL AND METHODS From 2000 to 2015, a retrospective analysis identified 300 patients with aGCT treated at our institution. Kaplan-Meier methods were used for analysis of progression-free survival (PFS) and overall survival (OS) according to the International Germ Cell Consensus Classification Group (IGCCCG). RESULTS Patients’ median age was 28 years. According to the IGCCCG, 57% had good-, 18.3% intermediate-, and 24.7% poor-risk disease. Median α-fetoprotein levels were 2.9, 243, and 3,998 ng/mL, and those of human chorionic gonadotropin were 0.4, 113, and 301.5 mUI/mL in IGCCCG good-, intermediate-, and poor-risk groups, respectively. At a median 46 months of follow-up, 93 PFS events and 45 deaths had occurred and estimated 5-year PFS and OS were 69% and 85%, respectively, including 83% and 95.3% in good-risk, 70.9% and 83.6% in intermediate-risk, and 35.1% and 62.2% in poor-risk patients, respectively. In multivariable analysis, Eastern Cooperative Oncology Group performance status ≥ 2 was a significant independent prognostic factor with a hazard ratio of 2.58 (95% CI, 1.55 to 4.29; P < .001) and 6.20 (95% CI, 2.97 to 12.92; P < .001) for PFS and OS, respectively. CONCLUSION Brazilian patients with aGCT in this cohort had similar outcomes as patients in the IGCCCG database. In comparison with contemporary series, patients with intermediate- and poor-risk aGCT had slightly inferior PFS and OS, possibly due to a high percentage of patients with poor performance status and less use of high-dose chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|